Hermed Capital

Hinova Pharmaceuticals Inc. is a drug discovery and development company based in Chengdu, China, with additional branches in Hong Kong, Texas, and Australia. Established in 2013, the company specializes in the research and manufacturing of innovative medicines to address unmet medical needs, particularly in oncology and metabolic diseases. Utilizing advanced technology platforms such as deuterium and PROTAC, Hinova develops both Best-in-class and First-in-class drugs. Its product pipeline includes the HC-1119 androgen receptor antagonist and HC-1102 androgen receptor inhibitors, which target advanced prostate cancer and breast cancer. The company's commitment lies in providing safe, effective, and affordable treatments while retaining global rights and interests in its drug portfolio.

Prognos Health is a healthcare technology company specializing in advanced analytics. Its platform, prognosFACTOR, enables querying of billions of de-identified patient records for clinically-focused insights within minutes. The platform facilitates the purchase and use of HIPAA-compliant data for applications such as cohort design, patient journey studies, and health outcomes analysis. Prognos Health serves 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

Spineology Inc. is a medical device company specializing in anatomy-conserving technology solutions for spine surgery. Founded in 1996 and headquartered in Saint Paul, Minnesota, the company offers a range of products designed to enhance surgical efficiency and improve patient outcomes. Its product lineup includes pedicular fixation systems like Threshold and Fortress, interbody fusion solutions such as Duo and Rampart, and biologics like the Prime liquid tissue matrix and Armor amniotic wound covering. Additionally, Spineology provides a variety of surgical instruments, including the Capture facet fixation system, VIA spinous process fixation system, and Medius midline retractor system, among others. The company focuses on using minimally invasive techniques to reduce post-operative pain and facilitate quicker recovery for patients suffering from spinal-related issues.

Aadi Bioscience is a clinical-stage biopharmaceutical company developing precision therapies for cancers driven by mTOR pathway alterations. It focuses on targeted mTOR inhibitors to treat genetically defined cancers, including alterations in TSC1 or TSC2 genes, where conventional inhibitors have struggled with pharmacology, delivery, safety, or tumor targeting. The company is advancing ABI-009, a clinical-phase mTOR inhibitor intended for oncology indications as well as cardiovascular and metabolic contexts. Aadi aims to bring transformative therapies to patients with ultra-rare cancers such as PEComa, and it traces its origins to an earlier name, with its operations based in Pacific Palisades, California, and a founding year of 2011.

Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Minneapolis, Minnesota, dedicated to developing innovative treatments for kidney and neurological diseases. The company's lead drug candidate, DM199, is a recombinant human tissue kallikrein-1 protein. It has completed Phase Ib clinical trials for treating moderate to severe chronic kidney disease linked to Type I or Type II diabetes and is undergoing Phase II trials for acute ischemic stroke. DM199 has been administered to nearly 100 patients, demonstrating a safe and well-tolerated profile. Additionally, DiaMedica is developing DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. The company has a collaboration agreement with Ahon Pharmaceutical Co Ltd. to further develop and commercialize DM199 for acute ischemic stroke. DiaMedica Therapeutics was founded in 2000 and was previously known as DiaMedica Inc. before rebranding in December 2016.

Applied StemCell Inc. is a biotechnology company specializing in the development of animal and cell line models for drug discovery and diagnostics. The company utilizes its proprietary TARGATT™ gene modification technology to create site-specific Knockin mouse, rat, and human cell line models, making the process efficient for both pharmaceutical and academic researchers. Applied StemCell's offerings include a range of genetically modified models, such as Knockin, Knockout, and transgenic mice, as well as humanized mouse models and gene-modified induced pluripotent stem cells (iPSCs). In addition to model development, the company provides optimized stem cell culture products and gene engineering services for mammalian cells. By continuously enhancing its technologies and product lines, Applied StemCell aims to meet the evolving needs of the biomedical community and support advancements in molecular diagnostics and personalized medicine.

Ativa Medical Corporation is a medical device manufacturing company based in Saint Paul, Minnesota, founded in 2008. The company specializes in developing and commercializing point of care testing medical diagnostics products aimed at decentralized healthcare settings. Ativa Medical focuses on providing rapid diagnostic test results for critical hematology and clinical chemistry tests, utilizing advanced microfluidics technology. Its product offerings include analyzers and disposable test cards designed for trauma, pediatric, oncology, and geriatric patients. These products cater to various healthcare environments, including hospital departments, physician's offices, and remote healthcare clinics, enhancing the speed and accessibility of medical diagnostics.